Ep. 369 - ASCO advances, China innovation & U.S. science under threat – BioCentury This Week

Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China ...

Poddgruvan

Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Ep. 374 - Parkinson's deep dive & FDA trial reforms

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Ep. 371 - Moving faster at the academia-industry interface

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

Ep. 368 - ASCO Preview, China Policy, ADC Linkers

Ep. 367 - FDA, obesity targets and the rise of DACs

Ep. 366 - Europe's need for speed: Bio€quity takeaways

Ep. 365 - Thin ice for Makary, redosing AAVs